Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices

Clinical Infectious Diseases

Volumn 33, Issue 10, 2001, Pages 1692-1696

  Singh, N ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT; PYRROLE DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; DRUG USE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST SUSCEPTIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; MYCOSIS; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; CAUSALITY; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; OPPORTUNISTIC INFECTIONS;

EID: 0035889523     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/323895     Document Type: Review

References (48)

1. Aspergillosis: An increasing problem in tertiary care hospitals?
2. Trends in postmortem epidemiology of invasive fungal infections at a university hospital
3. Epidemiology of fungal infections in hematopoietic stem cell transplant recipients in the 1990s
4. Invasive mold infections in allogeneic bone marrow transplant recipients
5. Risk factors for invasive fungal infections complicating orthotopic liver transplantation
6. Infections after liver transplantation: An analysis of 101 consecutive cases
7. Risk factors for systemic fungal infections in liver transplant recipients
8. Emerging trends in invasive mold infections in organ transplant recipients
9. Invasive aspergillosls in transplant recipients
10. Aspergillosis case-fatality rate: Systematic review of the literature
11. Burden of aspergillosis-related hospitalizations in the United States
12. Efficacy of caspofungin as salvage therapy in invasive aspergillosis compared to standard therapy in historical cohort
13. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
14. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: Case report and literature review of central nervous system pseudallescheriasis
15. Variation in rates of candida bloodstream infection in seven surgical ICUs and six neonatal ICUs
16. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
17. Effect of fluconazole administration in critically ill patients
18. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units
19. The epidemiology of hematogenous candidiasis caused by different Candida species
20. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
21. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
22. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients
23. Antifungal prophylaxis for solid organ transplant recipients: Seeking clarity amidst controversy
24. --selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors: A single-centre experience
25. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
26. Blood or marrow?
27. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial
28. The graft-vs.-leukemia effects of allogeneic cell therapy
29. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: Graft-vs.-host disease and graft-vs.-leukemia effect
30. Candida infection in pediatric liver transplant recipients
31. Liver transplantation: Current status and novel approaches to liver replacement
32. Primary liver transplantation without transfusion of red blood cells
33. Biliary reconstruction without T tubes or stents in liver transplantation: Report of 502 consecutive cases
34. Trends in invasive fungal infections in liver transplant recipients: Correlation with evolution in transplantation practices
35. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis
36. Susceptibility of Candida glabrata strains with reduced susceptibility of azoles in four liver transplant patients with invasive candidiasis
37. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
38. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients
39. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: Analysis of aetiology risk factors and outcome
40. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: US Renal Transplant Mycophenolate Mofeteil Study Group
41. Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
42. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
43. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplantation rejection
44. Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus
45. Cryptococcus neoformans infection in organ transplant: Correlates of variability in clinical characteristics and outcome
46. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685, 818 are toxic to Cryptococcus neoformans by inhibition of a common target protein
47. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin
48. Present status of detection of antifungal resistance: The perspective from both sides of the ocean